论文部分内容阅读
目的 观察 Ki6 7在颅内转移癌和胶质瘤中表达及数量变化 .方法 运用免疫组化 SABC法检测人脑 5 0例胶质瘤 (JPA- L GA 15例、AA 15例、GBM 2 0例 )、14例转移癌、2 0例脑膜瘤 (良性 17例、恶性 3例 )中 Ki6 7阳性指数的变化 .正常脑组织标本 3例作为阴性对照 .结果 在颅内肿瘤中 ,JPA- L GA的 Ki6 7L I为 0 .5 1± 0 .49,AA为 4.37± 2 .44 ,GBM为 6 .6 9± 1.79,转移癌为 14.3± 6 .10 ,恶性脑膜瘤为10 .2 1± 6 .2 7,良性脑膜瘤为 0 .5 8± 1.79. JPA- L GA,AA,GBM组间有显著性差异 (P<0 .0 1) .胶质瘤 - 级与良性脑膜瘤组间无明显差异 (P=0 .892 ) .结论 Ki6 7表达与脑转移癌和胶质瘤细胞增殖活性有关 ,可用以辅助鉴别诊断良恶性病变 ,还可作为评估脑胶质瘤恶性程度的一项参考指标 .
Objective To observe the expression and quantity changes of Ki67 in intracranial metastases and gliomas. Methods Immunohistochemical SABC method was used to detect 50 human gliomas (JPA-LGA, AA 15 and GBM 2 0). Cases), 14 cases of metastatic carcinoma, 20 cases of meningiomas (benign 17 cases, 3 cases of malignant) Ki67 positive index changes. 3 cases of normal brain tissue specimens as a negative control. Results in intracranial tumors, JPA-L The Ki of Ki6 7L I in GA was 0.51±0.49, AA was 4.37±2.44, GBM was 6.6.9±1.79, metastatic carcinoma was 14.3±6.10, and malignant meningioma was 10.21±. 6.7 Benign meningiomas were 0.58±1.79. There was a significant difference between the JPA-LGA, AA, and GBM groups (P<0.01). Gliomas-grade and benign meningiomas There was no significant difference (P=0.892). Conclusions Ki67 expression is related to brain metastases and glioma cell proliferation activity. It can be used to assist in the differential diagnosis of benign and malignant lesions, and it can also be used as a measure of malignant degree of gliomas. reference indicator .